Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,54 USD | +12,74% | +16,45% | -23,04% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 36,89 mln. 34,5 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 72,59% |
Recentste transcriptie over NRx Pharmaceuticals, Inc.
1 dag | +12,74% | ||
1 week | +16,45% | ||
Lopende maand | -24,98% | ||
1 maand | -31,40% | ||
3 maanden | -7,38% | ||
6 maanden | +26,43% | ||
Lopend jaar | -23,04% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Willard
CEO | Chief Executive Officer | 63 | 12-07-22 |
Jonathan Javitt
FOU | Founder | 67 | 18-09-17 |
Richard Narido
DFI | Director of Finance/CFO | 46 | 13-09-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Javitt
FOU | Founder | 67 | 18-09-17 |
Stephen Willard
CEO | Chief Executive Officer | 63 | 12-07-22 |
Janet Rehnquist
BRD | Director/Board Member | - | 27/12 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 3,54 | +12,74% | 280 114 |
25-04-24 | 3,14 | +0,64% | 102 032 |
24-04-24 | 3,12 | +2,30% | 97 946 |
23-04-24 | 3,05 | +1,67% | 106 468 |
22-04-24 | 3 | -1,32% | 211 625 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenKwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-23,04% | 36,89 mln. | |
+1,51% | 42,75 mld. | |
+8,57% | 41,34 mld. | |
+49,22% | 41,61 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |